Lucas Ward Profile - Ascendiant Analyst
18 Followers
Lucas Ward's Stock Coverage
| VVOSVivos Therapeutics | Jun 04, 2026 | BUY | Reiterated | $3.10 | 12Ratings | -50.26% | ||
| ACONAclarion, Inc. | May 28, 2026 | BUY | Reiterated | $7.50 | 8Ratings | -74.74% | ||
| SXTP60 Degrees Pharmaceuticals, Inc. | May 22, 2026 | BUY | Reiterated | $3.70 | 10Ratings | -74.27% | ||
| LIQTLiqTech International | May 20, 2026 | BUY | Reiterated | $4.40 | 10Ratings | -41.31% | ||
| HSCSHeart Test Laboratories, Inc. | Mar 23, 2026 | BUY | Reiterated | $8.00 | 12Ratings | -32.77% | ||
| VMARVision Marine Technologies | Apr 30, 2025 | BUY | Reiterated | $10.00 | 5Ratings | -98.94% |
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed. See how TipRanks ranks experts and calculates performance.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >Lucas Ward activity FAQ
What is the performance of Lucas Ward's recommendations?
The percentage of profitable recommendations made by Lucas Ward is 15.00%, and the average return per transaction is -58.30%.
What stocks does Lucas Ward cover?
Lucas Ward mostly covers Vivos Therapeutics, Aclarion, Inc., 60 Degrees Pharmaceuticals, Inc. stocks.
What was Lucas Ward's most profitable rating?
Lucas Ward’s most profitable rating was a buy on Vivos Therapeutics stock on Aug 20, 2024. The return on the trade was 35.40%.
Where can I see a list of stock analyst ratings?
You can see a list of daily stock analyst ratings here.
What are the most recommended stocks by analysts?
You can see a list of the most recommended stocks by analysts here